Analyst Reco. Mersana Therapeutics, Inc.

Equities

MRSN

US59045L1061

Market Closed - Nasdaq Other stock markets 04:00:00 2024-06-07 pm EDT			5-day change	1st Jan Change
2.14 ^USD	-3.39%		-8.15%	-7.76%

May. 09	Transcript : Mersana Therapeutics, Inc., Q1 2024 Earnings Call, May 09, 2024
May. 09	Earnings Flash (MRSN) MERSANA THERAPEUTICS Posts Q1 Revenue $9.2M, vs. Street Est of $8.5M	MT

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

JPMorgan Upgrades Mersana Therapeutics to Neutral From Underweight, Price Target is $5	Mar. 19	MT
Truist Securities Upgrades Mersana Therapeutics to Buy From Hold, Price Target is $9	Feb. 29	MT
Guggenheim Upgrades Mersana Therapeutics to Buy From Neutral, Price Target is $7	Feb. 29	MT
Wedbush Upgrades Mersana Therapeutics to Outperform From Neutral, Notes Increased Confidence in Program; Adjusts PT to $7 From $2	Feb. 29	MT
Citigroup Upgrades Mersana Therapeutics to Buy From Neutral, Raises Price Target to $5 From $1	Dec. 04	MT
Baird Downgrades Mersana Therapeutics to Neutral From Outperform, Adjusts Price Target to $1 From $7	23-07-28	MT
SVB Securities Lowers Mersana Therapeutics Price Target to $4 From $15, Outperform Rating Maintained	23-07-27	MT
Guggenheim Downgrades Mersana Therapeutics to Neutral From Buy	23-07-27	MT
JPMorgan Downgrades Mersana Therapeutics to Underweight From Neutral	23-07-27	MT
Citigroup Downgrades Mersana Therapeutics to Neutral From Buy, Cuts Price Target to $1 From $10	23-07-27	MT
Wedbush Downgrades Mersana Therapeutics to Neutral From Outperform, Adjusts Price Target to $2 From $12	23-07-27	MT
Truist Securities Downgrades Mersana Therapeutics to Hold From Buy	23-07-27	MT
Citigroup Adjusts Price Target on Mersana Therapeutics to $10 From $15, Keeps Buy Rating	23-06-16	MT
JPMorgan Downgrades Mersana Therapeutics to Neutral From Overweight, Adjusts Price Target to $5 From $11	23-06-16	MT
Wedbush Cuts PT on Mersana Therapeutics to $12 From $17 After US FDA Places Partial Hold on Cancer Drug UpRi Trials; Keeps Outperform Rating	23-06-15	MT
Wedbush Adjusts Price Target on Mersana Therapeutics to $12 From $17, Maintains Outperform Rating	23-06-15	MT
Guggenheim Initiates Mersana Therapeutics With Buy Rating, $14 Price Target	23-06-15	MT
Citigroup Adjusts Price Target on Mersana Therapeutics to $15 From $12, Maintains Buy Rating	23-05-11	MT
JPMorgan Upgrades Mersana Therapeutics to Overweight From Neutral, Price Target is $10	23-03-16	MT
Truist Securities Adjusts Price Target on Mersana Therapeutics to $10 From $8, Maintains Neutral Rating	22-11-21	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Mersana Therapeutics, Inc.

Equities

MRSN

US59045L1061

Analyst Reco.

Filters